ArticleJournal of natural medicines2014
Pharmacokinetics study of asperosaponin VI and its metabolites cauloside A, HN saponin F and hederagenin.
Article in Journal of natural medicines, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 7 citations in OpenAlex.
- An updated review of the pharmacological effects and potential mechanisms of hederagenin and its derivatives.Frontiers in pharmacology · 2024Review
- Pharmacokinetics, Bioavailability, Excretion and Metabolism Studies of Akebia Saponin D in Rats: Causes of the Ultra-Low Oral Bioavailability and Metabolic Pathway.Frontiers in pharmacology · 2021Article
- Current knowledge and development of hederagenin as a promising medicinal agent: a comprehensive review.RSC advances · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This experiment's with aim was to study the pharmacokinetics of asperosaponin VI and its three metabolites (cauloside A, HN saponin F and hederagenin) via a sensitive high performance liquid chromatography connected with electrospray ionization triple quadrupole mass spectrum (HPLC-ESI-MS/MS). Chromatographic separation was achieved on a reverse phase C18 column with a gradient mobile phase of CH3CN-water with 0.1 % HCOOH at a flow rate of 0.3 mL/min. Sample analysis was simultaneously performed with a multiple reaction monitoring mode using target determination ions at m/z 927.5 → 603.4 for asperosaponin VI, m/z 811.1 → 603.4 for cauloside A, m/z 649.4 → 603.4 for HN saponin F, m/z 71.4 → 393.3 for hederagenin and m/z 307.0 → 161.1 for warfarin as the internal standard. The calibration curve was linear at the range of 0.25-500 ng/mL, and the lower limit of quantification was 0.25 ng/mL for each compound. While the precisely intra-assay and inter-assay variabilities were <9.5 and 7.8 %, respectively; accuracy was determined at the concentrations of 5, 25, 100 ng/mL for all the analytes with the relative standard deviation (%) no more than 15.0 %. Consequently, the validated method could be successfully and precisely applied to the pharmacokinetic study of asperosaponin VI and its metabolites. As a result, the pharmacokinetic parameters of cauloside A, HN saponin F and hederagenin such as T max were obtained at 9.33 ± 2.49, 7.33 ± 0.47 and 12.33 ± 2.36 h, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.